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Panitumumab is approved for RAS wild-type metastatic colorectal cancer and was evaluated in Phase III (PRIME, NCT00364013)
and Phase II (PEAK, NCT00819780) ﬁrst-line randomised studies. This retrospective analysis of these trials investigated
efﬁcacy and toxicity of panitumumab-based maintenance after oxaliplatin discontinuation in RAS wild-type patients. First-line
regimens were FOLFOX4  panitumumab in PRIME and mFOLFOX6 plus panitumumab or mFOLFOX6 plus bevacizumab in PEAK.
Outcomes included median progression-free survival (PFS) and overall survival (OS), from randomisation and oxaliplatin
discontinuation, and toxicity. Overall, median duration of panitumumab plus 5-ﬂuorouracil/leucovorin (5-FU/LV) maintenance
was 21 (interquartile range: 11–41) weeks; that of 5-FU/LV  bevacizumab maintenance was 16 (6–31) weeks. Median OS
from randomisation was 40.2 (95% conﬁdence interval: 30.3–50.4) and 39.1 (34.2–63.0) months for panitumumab plus
5-FU/LV maintenance and 24.1 (17.7–33.0) and 28.9 (21.0–32.0) months for 5-FU/LV  bevacizumab maintenance in PRIME
and PEAK, respectively. Median PFS from randomisation was 16.6 (11.3–23.6) and 15.4 (11.6–18.4) months for panitumumab
plus 5-FU/LV maintenance and 12.6 (9.4–16.2) and 13.1 (9.5–16.6) months for 5-FU/LV  bevacizumab maintenance in PRIME
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and PEAK, respectively. From oxaliplatin discontinuation, median OS was 33.9 (24.7–42.8) and 33.5 (24.5–54.9) months for
panitumumab plus 5-FU/LV maintenance and 16.4 (12.4–24.1) and 23.3 (15.7–26.3) months for 5-FU/LV  bevacizumab
maintenance in PRIME and PEAK, respectively; PFS was 11.7 (7.8–19.2) and 9.7 (5.8–14.8) months and 7.1 (5.6–10.2) and 7.0
(3.9–10.6) months, respectively. The most frequently reported adverse events were rash, fatigue and diarrhoea. Maintenance
of panitumumab plus 5-FU/LV after oxaliplatin discontinuation was well tolerated and may be an acceptable treatment
paradigm for patients demonstrating a good response to ﬁrst-line treatment. Prospective studies are warranted.
What’s new?
Panitumumab is an anti-EGFR antibody used in the treatment of RAS wild-type metastatic colorectal cancer. But is it useful for
long-term therapy in these patients, especially after more toxic therapies like oxaliplatin are discontinued? In this
retrospective analysis, the authors found that a maintenance regimen including panitumumab was well tolerated and may be
associated with better outcomes than non-panitumumab strategies. Patients who received panitumumab-based maintenance
therapy were also more likely to have had a good response to ﬁrst-line treatment. The results from this study indicate that
further, prospective studies are warranted.
Introduction
Panitumumab is a human anti-epidermal growth factor recep-
tor (EGFR) monoclonal antibody indicated in the treatment
of patients with RAS wild-type (WT) metastatic colorectal
cancer (mCRC).1,2 Panitumumab has been evaluated in
several randomised clinical trials in mCRC, including the
Phase III PRIME study (NCT00364013) and Phase II PEAK
study (NCT00819780), both of which included extended RAS
mutation testing (KRAS and NRAS exons 2, 3 and 4). Both
studies assessed the use of panitumumab as part of
oxaliplatin-containing ﬁrst-line therapy.3–6
Clinical trial data show that continuation of ﬁrst-line ther-
apy until disease progression occurs only in a subpopulation of
patients with mCRC, suggesting that systemic therapy is de-
escalated in many patients before progression.7,8 Considerations
around maintenance therapy are of particular importance when
drugs like oxaliplatin – associated with cumulative neurotoxic-
ity – form part of adopted regimens. Accumulating toxicity can
cause treatment discontinuation in responding patients and
negatively impact quality of life. In light of such issues, ‘stop-
go’ and/or maintenance strategies have been proposed.9–11
Evaluation of such treatment paradigms is somewhat compli-
cated by uncertainties around appropriate outcomes measures.
Despite these challenges, ‘stop-go’ and maintenance treatment
regimens have been shown to be effective (including with
respect to overall survival [OS] and progression-free survival
[PFS]), to have acceptable safety proﬁles,9,11 and may also
increase time to treatment failure.12 With respect to biologics,
data from Phase III maintenance trials are already available for
bevacizumab-based maintenance regimens.13,14
There is currently little evidence available from prospective
clinical trials focused on the role of anti-EGFR antibodies
in the maintenance setting, although available data are
encouraging.15–17 To date, the role of panitumumab in
maintenance therapy after discontinuation of oxaliplatin has
not yet been properly investigated. The aim of this retrospec-
tive analysis of the PRIME and PEAK trials was to investigate
the efﬁcacy and toxicity of panitumumab-based maintenance
treatment after discontinuation of oxaliplatin in a RAS WT
subgroup. Preliminary results have been presented in abstract
form.18
Materials and Methods
Study designs
As previously described,3,6 the PRIME study was a rando-
mised, open-label, Phase III clinical trial in which ﬂuorouracil,
leucovorin and oxaliplatin (FOLFOX4) was administered to
patients with mCRC, either alone or in combination with
panitumumab (6 mg/kg every 2 weeks), as ﬁrst-line treatment.
The PEAK study was a randomised, open-label, Phase II clini-
cal trial in which modiﬁed ﬂuorouracil, leucovorin and oxali-
platin (mFOLFOX6) was administered in combination with
either panitumumab (6 mg/kg every 2 weeks) or bevacizumab
(5 mg/kg every 2 weeks), as ﬁrst-line treatment.4,5 In both
trials, it was foreseen that FOLFOX-based treatment would
continue until progressive disease or unacceptable toxicity.
Oxaliplatin discontinuation was recommended if Grade 3 neu-
ropathy or other dose-limiting toxicity occurred. After discon-
tinuation of oxaliplatin, the investigator could continue with
existing 5-ﬂuorouracil-based treatment (i.e., 5-FU/LV) in the
absence or presence of panitumumab (or bevacizumab in the
case of the PEAK study). Oxaliplatin could also be restarted
during the follow-up period (i.e., ‘stop-go’ regimen) at the dis-
cretion of the investigator.
Populations
In brief, patients in the PRIME study were adults with previ-
ously untreated metastatic adenocarcinoma of the colon or
2 Panitumumab-based maintenance treatment
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rectum, and an Eastern Cooperative Oncology Group (ECOG)
performance status of 0–2.6 Patients in the PEAK study were
adults with metastatic adenocarcinoma of the colon or rectum
with unresectable metastatic disease, an ECOG performance
status of 0 or 1, and WT KRAS exon 2 (codons 12 and 13).
Patients in the PEAK study had not previously been treated
with chemotherapy, anti-EGFR therapy or bevacizumab for
mCRC.5 Only patients with RAS WT mCRC were included in
this retrospective analysis (i.e., patients without mutations in
tumour KRAS or NRAS exons 2 [codons 12/13], 3 [codons
59/61] and 4 [codons 117/146]).
Analyses
Outcomes of ﬁrst-line treatment were analysed in patients
who subsequently received maintenance therapy after discon-
tinuation of oxaliplatin and in patients who did not. Early
tumour shrinkage (ETS) was calculated and deﬁned as a
≥30% reduction in the sum of the longest diameters (mm) of
measurable target lesions at week 8, compared with baseline.
Depth of response (DpR) was calculated as the maximum per-
centage change from randomisation to nadir in patients who
had tumour shrinkage. In patients with tumour growth or no
change in tumour size, DpR was deﬁned as the percentage
change from randomisation to progression if the patient sub-
sequently progressed, or as ‘missing’ if the patient did not pro-
gress. DpR was positive if there was tumour shrinkage,
negative if there was tumour growth, and zero if there was no
change. Overall response rates were evaluated per modiﬁed
Response Evaluation Criteria in Solid Tumors (version 1.0).
Kaplan-Meier estimates and 95% conﬁdence intervals
(CI) were calculated by treatment group for duration of
response (for patients with an objective response on central
[PRIME] or local [PEAK] review); duration of clinical beneﬁt
(for patients with an objective response or stable disease); and
resection rates.
The following outcomes of maintenance therapy were cal-
culated using the Kaplan-Meier method: median PFS
(i.e., time from randomisation to disease progression or
death); OS (i.e., time from randomisation until death); OS
from oxaliplatin discontinuation (i.e., time from the start of
maintenance treatment until death); and PFS from oxaliplatin
discontinuation (i.e., time from the start of maintenance treat-
ment until disease progression or death). Toxicity was also
assessed via monitoring of adverse events occurring in ﬁrst
line and maintenance treatment or emerging during the main-
tenance treatment period (overall and Grade 3+).
Ethics approval and consent to participate
The PRIME and PEAK studies were conducted in accordance
with the Declaration of Helsinki. Study protocols were approved
by an independent ethics committee at each study centre. All
patients provided informed consent.
Results
Patients, demographics and baseline characteristics
Of the 665 patients with RAS WT mCRC who participated in
the two studies, 83 received panitumumab plus 5-FU/LV main-
tenance therapy and 71 received 5-FU/LV  bevacizumab
maintenance therapy. Five hundred and eleven patients did not
receive maintenance therapy. Baseline demographics and dis-
ease characteristics, as well as details of ﬁrst-line treatment, for
each study are summarised in Table 1, and pooled data are pro-
vided in Supporting Information Table S1.
Outcomes during ﬁrst-line treatment
First-line treatment outcomes are summarised in Table 2;
pooled data are provided in Supporting Information Table S2.
The median (range) number of oxaliplatin infusions that
patients received during ﬁrst-line treatment was 12 (2–31)
and 11 (3–21) for panitumumab plus 5-FU/LV in PRIME and
PEAK, respectively, 13 (5–41) for 5-FU/LV maintenance in
PRIME and 12 (3–9) for 5-FU/LV plus bevacizumab mainte-
nance in PEAK. Patients who received panitumumab plus
5-FU/LV maintenance therapy were more likely to have
received ≥9 months of ﬁrst-line treatment, to have experi-
enced ETS and to have had higher rates of complete response
and partial response than patients who received maintenance
therapy with 5-FU/LV  bevacizumab. These patients also
had improved DpR, duration of response and duration of
clinical beneﬁt.
Outcomes during maintenance treatment
The median (interquartile range) duration of panitumumab
plus 5-FU/LV maintenance therapy was 16 (8–41) weeks in
PRIME and 28 (14–46) weeks in PEAK, while that of 5-FU/
LV  bevacizumab maintenance therapy was 15 (6–31) and
16 (9–30) weeks in PRIME and PEAK, respectively (Table 3).
In patients who received panitumumab plus 5-FU/LV mainte-
nance therapy, median OS from randomisation was longer
compared to those receiving 5-FU/LV or 5-FU/LV plus beva-
cizumab maintenance therapy (40.2 [30.3–50.4] and 39.1
[34.2–63.0] months compared with 24.1 [17.7–33.0] and 28.9
[21.0–32.0] months in PRIME and PEAK, respectively
(Table 3; Fig. 1). From oxaliplatin discontinuation, OS was
33.9 (24.7–42.8) and 33.5 (24.5–54.9) months in patients who
received panitumumab plus 5-FU/LV maintenance therapy in
PRIME and PEAK, respectively, and 16.4 (12.4–24.1) and 23.3
(15.7–26.3) months for those receiving 5-FU/LV  bevacizu-
mab maintenance therapy. In pooled analysis, median OS
from randomisation was 40.2 (95% CI: 35.6–47.4) months for
patients receiving panitumumab plus 5-FU/LV, compared
with 25.3 (21.0–31.9) months in those receiving 5-FU/
LV  bevacizumab maintenance therapy and median OS
from oxaliplatin discontinuation was 33.9 (28.4–41.3) and
18.8 (15.4–24.1) months, respectively (Supporting Information
Table S3).
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Median PFS from randomisation was 16.6 (11.3–23.6)
and 15.4 (11.6–18.4) months in patients receiving panitu-
mumab plus 5-FU/LV maintenance in PRIME and PEAK,
respectively, compared with 12.6 (9.4–16.2) months in those
receiving 5-FU/LV maintenance therapy in PRIME and 13.1
(9.5–16.6) months in those receiving 5-FU/LV plus bevaci-
zumab maintenance therapy in PEAK (Table 3). Median
PFS from oxaliplatin discontinuation was 11.7 (7.8–19.2)
and 9.7 (5.8–14.8) months for patients receiving panitumu-
mab plus 5-FU/LV maintenance in PRIME and PEAK,
respectively, and 7.1 (5.6–10.2) and 7.0 (3.9–10.6) months
for those receiving 5-FU/LV  bevacizumab maintenance
therapy (Table 3; Fig. 2). In pooled analysis, median PFS
from randomisation was 15.4 (95% CI: 12.6–18.4) months
for patients receiving panitumumab plus 5-FU/LV, com-
pared with 13.1 (11.3–15.4) months in those receiving
5-FU/LV  bevacizumab maintenance therapy and median
PFS from oxaliplatin discontinuation was 10.2 (7.8–14.8)
and 7.1 (6.6–9.2) months, respectively (Supporting Informa-
tion Table S3). Overall, 22% of patients receiving panitumu-
mab plus 5-FU/LV maintenance restarted oxaliplatin during
the follow-up period, compared with 10% of those receiving
5-FU/LV  bevacizumab maintenance (Supporting Infor-
mation Table S3).
Toxicity
The adverse events that occurredmost commonly duringmainte-
nance therapy were rash, fatigue and diarrhoea (Table 4). These
events were also the most common adverse events to emerge dur-
ing ﬁrst-line therapy (Supporting Information Table S4). In the
PRIME study, maintenance treatment-emergent dry skin was
reported in 11.5% of patients receiving panitumumab plus
5-FU/LV maintenance therapy and 2.4% of patients receiving
5-FU/LV maintenance therapy. In the PEAK study, dry skin was
reported in 19.4% of patients receiving panitumumab plus
5-FU/LV maintenance therapy and 0% of patients receiving
5-FU/LV + bevacizumab maintenance therapy (Table 4). The
most frequent maintenance treatment-emergent Grade 3+
adverse events were paraesthesia (PRIME) and acne (PEAK) in
the panitumumab plus 5-FU/LV maintenance groups, and
peripheral neuropathy in the 5-FU/LV  bevacizumab mainte-
nance groups (Table 4).
Discussion
While the European Society for Medical Oncology mCRC
guidelines recommend anti-EGFR monoclonal antibodies as a
ﬁrst-line treatment option,2 little evidence is available on de-
escalation strategies from EGFR-based combination regimens.
Table 1. Baseline demographics and disease characteristics
PRIME PEAK
Maintenance therapy Maintenance therapy
Pmab +
5-FU/LV
(n = 52)
5-FU/LV
(n = 41)
None
(n = 406)
Pmab +
5-FU/LV
(n = 31)
5-FU/LV +
bev (n = 30)
None
(n = 105)
Median age (range), years 59 (41–79) 62 (24–78) 61 (27–82) 62 (23–75) 61 (39–79) 60 (39–82)
Male sex, n (%) 31 (60) 26 (63) 266 (66) 21 (68) 18 (60) 73 (70)
BRAF status, n (%)
Wild-type 49 (94) 35 (85) 349 (86) 27 (87) 28 (93) 97 (92)
Mutant 3 (6) 4 (10) 46 (11) 4 (13) 2 (7) 8 (8)
Unknown 0 (0) 2 (5) 11 (3) 0 (0) 0 (0) 0 (0)
Tumour location, n (%)
Left sided 40 (77) 27 (66) 261 (64) 21 (68) 18 (60) 68 (65)
Right sided 6 (12) 7 (17) 75 (18) 8 (26) 5 (17) 23 (22)
Unknown 6 (12) 7 (17) 70 (17) 2 (6) 7 (23) 14 (13)
Site of metastases, n (%)
Liver + other 35 (67) 34 (83) 269 (66) 17 (55) 9 (30) 50 (48)
Liver only 12 (23) 4 (10) 73 (18) 10 (32) 10 (33) 24 (23)
Other only 5 (10) 3 (7) 64 (16) 4 (13) 11 (37) 31 (30)
ECOG performance status 0, n (%) 34 (65) 24 (59) 226 (56) 21 (68) 21 (70) 62 (59)
Stage IV disease at diagnosis,1 n (%) 35 (67) 33 (80) 302 (74) 22 (71) 19 (63) 73 (70)
Prior adjuvant chemotherapy, n (%) 13 (25) 4 (10) 62 (15) 2 (6) 6 (20) 23 (22)
5-FU, 5-fluorouracil; bev, bevacizumab; ECOG, Eastern Cooperative Oncology Group; LV, leucovorin; Pmab, panitumumab.
1Presence of Stage IV disease at baseline was derived by taking date of metastases – date of primary diagnosis (allowing a 2-month window).
4 Panitumumab-based maintenance treatment
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Our study, therefore, addresses a highly relevant clinical sce-
nario, where evidence is currently limited.
One of the challenges in assessing the effects of mainte-
nance therapy is the selection of appropriate outcome mea-
sures. Although of most interest to patients, the use of OS as
an endpoint to evaluate the efﬁcacy of maintenance treatment
regimens is hampered by the need for extended follow-up and
the potential impact of subsequent and prior ﬁrst-line thera-
pies.11,14,19 It has therefore been argued that other endpoints
are more relevant to the maintenance setting.11,19,20 For exam-
ple, some have argued that PFS20 or time-to-failure-of-strat-
egy11,19 are more appropriate endpoints, while others caution
that such endpoints can be difﬁcult for patients to under-
stand.11 An analysis of over a 1,000 patients with mCRC
found that time-to-failure-of-strategy and duration of disease
control correlate well with OS.21 In the present analysis, we
assessed PFS and OS; time-to-failure-of-strategy data could
not be derived from the studies. Additionally, toxicity out-
comes were evaluated.
Literature evidence suggests that – based on randomised
Phase II trials – anti-EGFR-based maintenance therapy is
feasible in mCRC patients after oxaliplatin-based induction
regimens. The MACRO-2 study evaluated maintenance cetux-
imab with or without mFOLFOX until progression in KRAS
WT mCRC patients and reported non-inferiority for 9-month
PFS rate (the primary endpoint) and OS.15 Similarly, the
COIN-B study evaluated ﬁrst-line treatment with intermittent
FOLFOX plus either intermittent or continuous cetuximab.
Failure-free survival at 10 months was 50% in the intermittent
group and 52% in the continuous group.16
Several other maintenance scenarios are currently under
investigation, such as that studied in the SAPPHIRE trial,
which compares continuation of panitumumab plus mFOL-
FOX6 with panitumumab plus 5-FU/LV maintenance22 and
recently reported 9-month PFS rates of 45% and 47%, respec-
tively.22,23 Other ongoing trials are expected to clarify the role
of panitumumab plus 5-FU/LV in this setting: the VALEN-
TINO non-inferiority trial,24 which recently showed that pani-
tumumab alone was inferior to panitumumab plus 5-FU/LV
for unresectable RAS WT mCRC patients, after eight cycles of
FOLFOX4 plus panitumumab induction treatment,25 and the
PanaMa superiority trial, which will compare panitumumab
Table 2. Initial treatment and response to first-line therapy
PRIME PEAK
Maintenance therapy Maintenance therapy
Pmab + 5-FU/LV
(n = 52)
5-FU/LV
(n = 41)
None
(n = 406)
Pmab + 5-FU/LV
(n = 31)
5-FU/LV + bev
(n = 30)
None
(n = 105)
Median number of oxaliplatin
infusions before maintenance
therapy (range)
12 (2–31) 13 (5–41) 11 (1–60) 11 (3–21) 12 (3–19) 10 (1–35)
First-line study drug exposure,
n (%)
<3 months 0 (0) 0 (0) 83 (20) 0 (0) 0 (0) 27 (26)
≥3 to <6 months 5 (10) 3 (7) 131 (32) 1 (3) 2 (7) 37 (35)
≥6 to <9 months 8 (15) 13 (32) 93 (23) 5 (16) 8 (27) 23 (22)
≥9 months 39 (75) 25 (61) 99 (24) 25 (81) 20 (67) 18 (17)
Early tumour shrinkage ≥30%,
n (%)
33 (63) 15 (37) 165 (41) 22 (71) 16 (53) 46 (44)
Best overall response, n (%)
Complete response 1 (2) 0 (0) 1 (<1) 3 (10) 1 (3) 4 (4)
Partial response 41 (79) 23 (56) 199 (49) 24 (77) 22 (73) 51 (49)
Stable disease 9 (17) 17 (41) 141 (35) 4 (13) 7 (23) 37 (35)
Progressive disease 1 (2) 1 (2) 47 (12) 0 (0) 0 (0) 5 (5)
Not available 0 (0) 0 (0) 18 (4) 0 (0) 0 (0) 8 (8)
Median duration of response
(95% CI), months
14.8
(9.6–22.1)
14.3
(8.2–16.6)
9.3
(8.3–10.1)
13.2
(9.2–18.7)
10.3
(7.4–14.8)
9.2
(7.9–11.1)
Median duration of clinical
benefit1 (95% CI), months
14.8
(9.6–22.0)
11.1
(8.2–14.3)
8.6
(7.6–9.4)
13.7
(9.6–16.8)
11.2
(7.7–14.8)
8.8
(7.3–10.8)
Median depth of response
(IQR), %
64 (48–78) 56 (43–68) 46 (22–68) 72 (50–85) 48 (39–61) 52 (29–86)
Resection, n (%)
Any 7 (13) 4 (10) 53 (13) 1 (3) 4 (13) 18 (17)
Complete 5 (10) 4 (10) 36 (9) 0 (0) 2 (7) 14 (13)
5-FU, 5-fluorouracil; bev, bevacizumab; CI, confidence interval; IQR, interquartile range; LV, leucovorin; Pmab, panitumumab.
1Complete or partial response, or stable disease.
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plus 5-FU/LV vs. 5-FU/LV alone as maintenance strategies.26
In the current analysis, panitumumab plus 5-FU/LV mainte-
nance therapy was associated with encouraging median OS
and PFS rates, both from randomisation and from the time of
oxaliplatin discontinuation.
Although practice-deﬁning data are available regarding
bevacizumab-based maintenance therapy, the implications of
these remain somewhat unclear. Statistically signiﬁcant results
have been reported with respect to PFS and time-to-failure-of-
strategy endpoints. For example, the CAIRO3 and AIO
KRK0207 trials suggested that maintenance strategies based
on ﬂuoropyrimidine plus bevacizumab might be regarded
as standard as they impact on PFS and time-to-failure-of-
strategy/PFS-2.13,14 Similarly, results from a Phase III study of
bevacizumab and capecitabine maintenance after discontinua-
tion of oxaliplatin also suggest a potential beneﬁt on PFS.27
However, OS data from these studies appear conﬂicting. The
AIO KRK0207 trial did not ﬁnd a difference in OS between
treatment groups, although the limited feasibility of sequential
therapy prevented the authors from drawing clear conclu-
sions.14 In CAIRO3, a trend for improved OS failed to reach
the level of signiﬁcance.13 A Swiss Phase III study of mCRC
failed to demonstrate non-inferiority of bevacizumab continu-
ation (after induction with chemotherapy) compared with no
continuation, with respect to time-to-progression.28 Further-
more, the PRODIGE 9 Phase III trial of bevacizumab mainte-
nance treatment found no beneﬁt over observation alone,
against a range of endpoints.29 A meta-analysis of bevacizumab-
based maintenance therapy reported improvements in time-to-
failure-of-strategy and PFS, and a trend to improvements in OS,
compared with complete stop.30
As patients in this analysis of maintenance therapy are
anti-EGFR-experienced and a selection bias may therefore
exist, this should be borne in mind when considering the
observed toxicity proﬁles – patients who discontinued treat-
ment due to unacceptable toxicity were not evaluated. Panitu-
mumab is associated mainly with skin toxicity, and cutaneous
side effects of anti-EGFR antibodies can be dose-limiting
toxicities. Most clinical trials have focused on folliculitis or
acne-like rash, and prophylactic treatment using cyclines,
emollients and photoprotection measures are now recom-
mended.31,32 However, other side effects, such as xerosis or
paronychia, may also represent limiting toxicities in patients
for whom PFS in ﬁrst-line treatment exceeds 12 months.32,33
These toxicities may justify a ‘stop-go’ strategy for anti-EGFR
antibodies, as might the potential emergence of RAS muta-
tions or other less common genomic alterations associated
with acquired resistance to anti-EGFR therapy.34,35 Acquired
resistance in patients who previously responded to anti-EGFR
treatment may occur due to the emergence of RAS or EGFR
ectodomain mutations, suggesting that ongoing monitoring
of patients’ EGFR status during treatment may be
important.34–36 To this end, it is possible that use of liquid
biopsy before commencing maintenance treatment might be
valuable in identifying those patients most likely to beneﬁt.
The results of the current study support further investigation
Table 3. Treatment outcomes in patients receiving maintenance therapy after first-line treatment
PRIME PEAK
Pmab + 5-FU/LV
maintenance
(n = 52)
5-FU/LV
maintenance
(n = 41)
Pmab + 5-FU/LV
maintenance
(n = 31)
5-FU/LV + bev
maintenance
(n = 30)
Median duration of maintenance therapy (IQR), weeks 16 (8–41) 15 (6–31) 28 (14–46) 16 (9–30)
Restarted oxaliplatin during
follow-up, n (%)
13 (25) 2 (5) 5 (16) 5 (17)
Median OS from randomisation
(95% CI), months
40.2 (30.3–50.4) 24.1 (17.7–33.0) 39.1 (34.2–63.0) 28.9 (21.0–32.0)
Median PFS from randomisation
(95% CI), months
16.6 (11.3–23.6) 12.6 (9.4–16.2) 15.4 (11.6–18.4) 13.1 (9.5–16.6)
Median OS from oxaliplatin discontinuation
(95% CI), months
33.9 (24.7–42.8) 16.4 (12.4–24.1) 33.5 (24.5–54.9) 23.3 (15.7–26.3)
Median PFS from oxaliplatin discontinuation
(95% CI), months
11.7 (7.8–19.2) 7.1 (5.6–10.2) 9.7 (5.8–14.8) 7.0 (3.9–10.6)
Later-line anti-EGFR therapy, n (%) 13 (25) 11 (26.8) 13 (41.9) 15 (50)
Panitumumab 4 (7.7) 7 (17.1) 8 (25.8) 7 (23.3)
Cetuximab 10 (19.2) 4 (9.8) 5 (16.1) 9 (30)
Other 0 (0) 0 (0) 0 (0) 0 (0)
Later-line anti-VEGF therapy, n (%) 19 (36.5) 6 (14.6) 19 (61.3) 10 (33.3)
Bevacizumab 18 (34.6) 5 (12.2) 18 (58.1) 10 (33.3)
Other 1 (1.9) 1 (2.4) 1 (3.2) 0 (0)
5-FU, 5-fluorouracil; bev, bevacizumab; CI, confidence interval; EGFR, epidermal growth factor receptor; IQR, interquartile range; LV, leucovorin; OS,
overall survival; PFS, progression-free survival; Pmab, panitumumab; VEGF, vascular endothelial growth factor.
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of panitumumab maintenance in RAS WT mCRC patients,
and prospective Phase II studies are ongoing.24,26,37
The authors are aware that this analysis has some limita-
tions, inherent to its retrospective nature. The analyses and
results were exploratory and no formal statistical hypothesis
or comparisons between groups were made. There were rel-
atively small number of patients in both the panitumumab
plus 5-FU/LV maintenance and 5-FU/LV  bevacizumab
maintenance groups and initiation of maintenance therapy
occurred later than would be expected in prospective clini-
cal trials. Patients who discontinued oxaliplatin were per-
mitted to reintroduce it during the follow-up period
(i.e., ‘stop-go’ paradigm), which may have affected the out-
comes. Patients with early progression did not receive any
maintenance treatment and therefore an a priori selection
of patients with EGFR-dependent/chemosensitive disease
existed and is consistent with the high values reached by
the survival measures. The ﬁnding that patients who
received panitumumab plus 5-FU/LV maintenance were
more likely to have received ≥9 months of ﬁrst-line treat-
ment and had generally experienced greater beneﬁt from
ﬁrst-line treatment than those in other groups also suggests
the positive selection of patients with panitumumab/chem-
otherapy-sensitive tumours. Given the limited sample size
and the retrospective nature of the study, groups were not
perfectly balanced in terms of baseline demographics, for
example with respect to BRAF mutations, metastases and
prior adjuvant therapy.
Our analysis suggests that in a substantial number of
patients, no maintenance treatment was administered after
(a)
(b)
(c)
Figure 2. Progression-free survival from oxaliplatin discontinuation
(i.e., start of maintenance therapy) in (a) PRIME, (b) PEAK and (c)
pooled analysis of both trials. 5-FU, 5-ﬂuorouracil; bev, bevacizumab;
LV, leucovorin; PFS, progression-free survival; Pmab, panitumumab.
(a)
(b)
(c)
Figure 1. Overall survival from randomisation in (a) PRIME, (b) PEAK
and (c) pooled analysis of both trials. 5-FU, 5-ﬂuorouracil; bev,
bevacizumab; LV, leucovorin; Pmab, panitumumab.
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oxaliplatin discontinuation. Various factors may explain
these observations, including population bias, but these
interesting preliminary ﬁndings warrant further investiga-
tion of outcomes, including OS, of panitumumab plus
5-FU/LV maintenance therapy in mCRC. Also, patients
with best outcomes after intensive treatment were more
prevalent in the panitumumab plus 5-FU/LV maintenance
groups, opening the way to speculation on how optimal
pharmacological cytoreduction might improve the effective-
ness of anti-EGFR-based maintenance, or on potential syn-
ergistic effects of panitumumab and continued – even if de-
escalated – chemotherapy in hyper-responsive selected RAS
WT patients.
Conclusions
In this retrospective analysis, maintenance of panitumumab plus
5-FU/LV treatment after discontinuation of oxaliplatin was well
tolerated and PFS and OS were numerically longer when panitu-
mumab was part of the maintenance regime. Patients in the pani-
tumumab plus 5-FU/LV maintenance groups had a good
response to ﬁrst-line treatment, suggesting that for those patients
demonstrating such a response to ﬁrst-line treatment in clinical
practice, maintenance with panitumumab and ﬂuorouracil
might be an acceptable treatment paradigm. These results are in
concordance with those of previous Phase II trials that investi-
gated anti-EGFR antibodies in maintenance therapy. However,
the retrospective design of our study means that it is not possible
Table 4. Maintenance treatment-emergent adverse events reported in ≥20% of patients in either treatment group in PRIME or PEAK
Maintenance treatment-emergent
AEs, n (%)
PRIME PEAK
Pmab + 5-FU/LV
maintenance
(n = 52)
5-FU/LV
maintenance
(n = 41)
Pmab + 5-FU/LV
maintenance
(n = 31)
5-FU/LV + bev
maintenance
(n = 30)
All AEs Grade 3+ All AEs Grade 3+ All AEs Grade 3+ All AEs Grade 3+
Any 47 (90.4) 31 (59.6) 36 (87.8) 17 (41.5) 30 (96.8) 15 (48.4) 28 (93.3) 14 (46.7)
Rash 18 (34.6) 6 (11.5) 0 (0.0) 0 (0.0) 15 (48.4) 2 (6.5) 0 (0.0) 0 (0.0)
Diarrhoea 13 (25.0) 1 (1.9) 11 (26.8) 2 (4.9) 16 (51.6) 0 (0.0) 9 (30.0) 0 (0.0)
Fatigue 14 (26.9) 2 (3.8) 5 (12.2) 0 (0.0) 9 (29.0) 1 (3.2) 7 (23.3) 1 (3.3)
Neuropathy, peripheral 10 (19.2) 3 (5.8) 10 (24.4) 5 (12.2) 11 (35.5) 2 (6.5) 4 (13.3) 3 (10.0)
Hypomagnesaemia 10 (19.2) 4 (7.7) 1 (2.4) 0 (0.0) 10 (32.3) 2 (6.5) 1 (3.3) 0 (0.0)
Skin fissures 12 (23.1) 2 (3.8) 0 (0.0) 0 (0.0) 7 (22.6) 0 (0.0) 1 (3.3) 0 (0.0)
Conjunctivitis 11 (21.2) 2 (3.8) 2 (4.9) 0 (0.0) 5 (16.1) 0 (0.0) 1 (3.3) 1 (3.3)
Mucosal inflammation 11 (21.2) 1 (1.9) 2 (4.9) 0 (0.0) 5 (16.1) 0 (0.0) 0 (0.0) 0 (0.0)
Paraesthesia 11 (21.2) 9 (17.3) 9 (22.0) 3 (7.3) 5 (16.1) 2 (6.5) 1 (3.3) 0 (0.0)
Paronychia 11 (21.2) 0 (0.0) 0 (0.0) 0 (0.0) 4 (12.9) 0 (0.0) 0 (0.0) 0 (0.0)
Neutropenia 9 (17.3) 5 (9.6) 5 (12.2) 2 (4.9) 4 (12.9) 1 (3.2) 3 (10.0) 0 (0.0)
Dermatitis acneiform 9 (17.3) 4 (7.7) 0 (0.0) 0 (0.0) 3 (9.7) 0 (0.0) 0 (0.0) 0 (0.0)
Vomiting 8 (15.4) 0 (0.0) 5 (12.2) 0 (0.0) 4 (12.9) 0 (0.0) 3 (10.0) 0 (0.0)
Pruritus 8 (15.4) 1 (1.9) 2 (4.9) 0 (0.0) 1 (3.2) 0 (0.0) 0 (0.0) 0 (0.0)
Anorexia 8 (15.4) 0 (0.0) 3 (7.3) 0 (0.0) NR NR NR NR
Stomatitis 7 (13.5) 1 (1.9) 2 (4.9) 0 (0.0) 9 (29.0) 0 (0.0) 2 (6.7) 0 (0.0)
Acne 7 (13.5) 2 (3.8) 0 (0.0) 0 (0.0) 7 (22.6) 3 (9.7) 0 (0.0) 0 (0.0)
Asthenia 7 (13.5) 1 (1.9) 3 (7.3) 0 (0.0) 6 (19.4) 0 (0.0) 6 (20.0) 2 (6.7)
Dry skin 6 (11.5) 1 (1.9) 1 (2.4) 0 (0.0) 6 (19.4) 0 (0.0) 0 (0.0) 0 (0.0)
Nausea 7 (13.5) 1 (1.9) 8 (19.5) 0 (0.0) 5 (16.1) 0 (0.0) 5 (16.7) 0 (0.0)
Peripheral sensory neuropathy 7 (13.5) 2 (3.8) 3 (7.3) 1 (2.4) 5 (16.1) 0 (0.0) 3 (10.0) 2 (6.7)
Hypokalaemia 6 (11.5) 3 (5.8) 2 (4.9) 0 (0.0) 5 (16.1) 2 (6.5) 1 (3.3) 0 (0.0)
Decreased appetite 0 (0.0) 0 (0.0) 1 (2.4) 0 (0.0) 8 (25.8) 0 (0.0) 4 (13.3) 0 (0.0)
Nail disorder 6 (11.5) 0 (0.0) 0 (0.0) 0 (0.0) 4 (12.9) 0 (0.0) 0 (0.0) 0 (0.0)
Thrombocytopenia 6 (11.5) 1 (1.9) 3 (7.3) 0 (0.0) 4 (12.9) 0 (0.0) 2 (6.7) 0 (0.0)
Constipation 5 (9.6) 0 (0.0) 2 (4.9) 0 (0.0) 4 (12.9) 0 (0.0) 2 (6.7) 0 (0.0)
Palmar-plantar erythrodysaesthesia
syndrome
2 (3.8) 0 (0.0) 3 (7.3) 0 (0.0) 5 (16.1) 0 (0.0) 2 (6.7) 1 (3.3)
Abdominal pain 5 (9.6) 0 (0.0) 4 (9.8) 0 (0.0) 3 (9.7) 0 (0.0) 2 (6.7) 0 (0.0)
Arthralgia 4 (7.7) 0 (0.0) 0 (0.0) 0 (0.0) 3 (9.7) 0 (0.0) 2 (6.7) 0 (0.0)
5-FU, 5-fluorouracil; AE, adverse event; bev, bevacizumab; LV, leucovorin; NR, not recorded; Pmab, panitumumab.
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to conﬁrm whether the observed clinical beneﬁt is due to the
induction treatment (all drugs), the maintenance therapy or both.
The analyses also suggest that in a substantial number of patients,
no maintenance treatment was administered after oxaliplatin
discontinuation. The role of panitumumab maintenance after
withdrawal of oxaliplatin should be further investigated in pro-
spective trials that include a biomarker analysis, assessment of OS
and assessment of quality of life.
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